The common shares of Spackman Equities Group trades on the TSX Venture Exchange under the symbol SQG. Visit www.spackmanequities.com for further information.
Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate ...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
The FDA has expanded the label for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody. This enables the identification of patients with hormone receptor (HR)-positive, HER2-ultralow ...
If breast cancer is diagnosed at an early stage, it has a higher chance of being cured. Therefore, it is important that you get tests done at regular intervals as it can help in early diagnosis of ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study The article by Mascarenhas ...
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback